###### Key messages

-   **What is already known about this subject?**

-   Cilostazol, a phosphodiesterase III inhibitor, exhibits antiplatelet effect and inhibits neointimal hyperplasia and smooth muscle proliferation. However, its role in addition to dual antiplatelet therapy (DAPT) of aspirin and clopidogrel in patients undergoing percutaneous coronary intervention (PCI) is not well defined.
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-   **What does this study add?**

-   In patients undergoing PCI, addition of cilostazol to DAPT results in decreased platelet reactivity and a significant reduction in cardiovascular outcomes including stent thrombosis, even in the drug-eluting stent era.
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-   **How might this impact on clinical practice?**

-   The current study provides evidence to support use of cilostazol as an attractive and strong competitor for newer antiplatelet regimens and should be evaluated in future trials in patients undergoing PCI.

Introduction {#s1}
============

Dual antiplatelet therapy (DAPT) with aspirin and an ADP receptor inhibitor is the standard of care for patients undergoing percutaneous coronary intervention (PCI). However, there is significant interindividual variability in the extent of platelet inhibition achieved with clopidogrel.[@R1] Several studies have shown a correlation between high levels of on-treatment platelet reactivity (HTPR) and adverse cardiovascular outcomes, such that patients with HTPR (also called clopidogrel resistance) have a threefold to fivefold increased risk for recurrent ischaemic events.[@R4] [@R5] Cilostazol, a phosphodiesterase III inhibitor, exhibits its antiplatelet effects via inhibition of the conversion of cyclic AMP (cAMP) to 5\'-AMP causing a subsequent increase in cAMP within platelets, and has been shown to augment platelet inhibition when it is added to aspirin and clopidogrel as part of a triple therapy regimen.[@R6] [@R7] In addition, cilostazol inhibits neointimal hyperplasia and smooth muscle proliferation, and has the potential to reduce the risk of restenosis after coronary stent implantation.[@R8] Despite these pharmacologic effects, clinical results from observational and small randomised trials have not shown a consistent clinical benefit.

Our objective was to evaluate whether triple antiplatelet therapy (TAPT) with cilostazol (in addition to aspirin and clopidogrel) decreases platelet reactivity and reduces adverse cardiovascular (CV) outcomes when compared with a dual antiplatelet (DAPT) regimen of aspirin and clopidogrel alone.

Methods {#s2}
=======

Eligibility criteria {#s2a}
--------------------

We conducted a MEDLINE, EMBASE and CENTRAL search using the MeSH terms 'cilostazol' and 'randomised clinical trial'. We limited our search to trials involving human subjects through May 2014. The search terms were broad with no language restrictions imposed. We checked the reference lists of review articles and prior meta-analyses to assess for additional eligible studies. Corresponding authors of studies were contacted for further information if relevant data were not reported. Trials in abstract format without a manuscript published were also included in the analysis.

To be included for analysis, eligible trials had to fulfil the following criteria: (1) randomised clinical trials of TAPT (aspirin, clopidogrel and cilostazol) in comparison to DAPT (aspirin and clopidogrel); (2) enrolment of patients undergoing PCI with drug-eluting or bare metal stents and (3) follow-up of at least 2 weeks for trials reporting platelet reactivity outcomes and at least 1 month for trials reporting cardiovascular outcomes.

Selection and quality assessment {#s2b}
--------------------------------

Three authors (AS, BT and SB) independently reviewed trial eligibility and quality. Disagreements were resolved by consensus. Risk of bias was assessed using criteria recommended by the Cochrane Collaboration, specifically evaluating sequence generation of allocation; allocation concealment; blinding of participants, staff and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias.[@R12] Trials with high or unclear risk of bias for the first three criteria were considered as high bias risk trials and the rest as low bias risk trials.

Data extraction and synthesis {#s2c}
-----------------------------

The primary platelet reactivity outcome was differences in platelet reactivity unit (PRU) after treatment in TAPT versus DAPT groups. Secondary outcomes were percent platelet inhibition and rate of HTPR. We used a cut-off of PRU \>235 as the threshold for identifying patients with HTPR who may be at high risk for ischaemic or thrombotic events following PCI, as has been recommended by a recent consensus document.[@R13] Of note, definition of HTPR differed by study.

Our primary CV outcome was major adverse cardiovascular events (MACE), defined as death, myocardial infarction (MI) or target lesion revascularisation (TLR). We evaluated secondary CV outcomes of death, cardiovascular death, MI, stent thrombosis, TLR and target vessel revascularisation (TVR). Safety outcomes of major bleeding, minor bleeding, any (major or minor) bleeding and drug discontinuation due to adverse effects were also evaluated. The definitions of bleeding varied between the trials. Given the lack of consistent reporting of the Academic Research Consortium definitions of stent thrombosis from the studies, we used the individual trial protocol definitions of stent thrombosis.

Statistical analysis {#s2d}
--------------------

We performed an intention to treat meta-analysis in line with recommendations from the Cochrane Collaboration and the PRISMA Statement[@R14] [@R15] and used standard software for statistical analysis (STATA V.9.0, STATA Corp, Texas, USA). Heterogeneity was assessed using the I^2^ statistic, defined as the proportion of total variation observed between the trials attributable to differences between trials rather than sampling error (chance), with values \<25% considered as low and \>75% as high.[@R16] The pooled effect for each grouping of trials was derived from the point estimate for each separate trial weighted by the inverse of the variance (1/SE^2^). Continuous variable outcomes (PRU, per cent platelet inhibition) between the groups were compared with both a fixed effect model using the inverse variance method and a random effects model using the DerSimonian and Laird method. For cardiovascular outcomes, rates were expressed per patient-years to adjust for the varying duration of follow-up. Results were therefore reported as incident rate ratios (IRR) and 95% CIs with the use of both a fixed effect model using the method of Mantel and Haenszel and a random effects model using the method of DerSimonian and Laird, with the estimate of heterogeneity being taken from the Mantel-Haenszel model. Publication bias was estimated using the weighted regression tests of Begg and Egger.[@R12]

For platelet reactivity indices, analyses were stratified based on whether standard-dose (75 mg) or high-dose (150 mg) clopidogrel was used in the DAPT arm. In addition, further sensitivity analyses were performed based on the cohort enrolled: (1) acute coronary syndrome (ACS) versus not; and (2) enrolment of patients with HTPR at baseline versus not. For cardiovascular outcomes, analyses were stratified based on stent type---drug eluting stent (DES) versus Bare metal stent (BMS). A p value of \<0.05 was considered significant.

Results {#s3}
=======

Study selection {#s3a}
---------------

We identified 41 trials that satisfied the inclusion criteria ([figure 1](#OPENHRT2014000068F1){ref-type="fig"}). Seventeen trials reported platelet reactivity outcomes of which 10 comparator arms used high dose (150 mg) of clopidogrel. A total of 34 trials reported CV outcomes, the majority (25 trials) of which used DES.

![Study selection.](openhrt2014000068f01){#OPENHRT2014000068F1}

Baseline characteristics {#s3b}
------------------------

The baseline characteristics, inclusion criteria and quality assessment are summarised in [tables 1](#OPENHRT2014000068TB1){ref-type="table"}[](#OPENHRT2014000068TB2){ref-type="table"}[](#OPENHRT2014000068TB3){ref-type="table"}--[4](#OPENHRT2014000068TB4){ref-type="table"}. In order to quantify platelet reactivity outcomes, we evaluated 17 trials with 20 comparator arms and 5056 patients. The median follow-up was 30 days and although the definition of HTPR was heterogeneous, all trials used the VerifyNow P2Y12 assay to measure platelet reactivity. The analysis of cardiovascular outcomes included 34 trials with 14 119 patients. The mean age of study participants was between 56.3 and 67.5 years, 37.9% of the patients had diabetes and the majority (77.6%) underwent PCI with DES.

###### 

Baseline characteristics of included trials for platelet reactivity outcomes

  Trial                      Year   N      Comparison                                              SD or HD (DAPT group)   Mean age (years)   Follow-up (days)
  -------------------------- ------ ------ ------------------------------------------------------- ----------------------- ------------------ ------------------
  ACCEL-AMI[@R29]            2009   90     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   Both                    62                 30
  ACCEL-LOADING-ACS[@R30]    2012   218    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   SD                      63                 30
  ACCEL-POLYMORPHISM[@R31]   2010   134    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   HD                      63                 30
  ACCEL-PPI[@R32]            2012   90     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   HD                      NR                 30
  ACCEL-RESISTANCE[@R33]     2009   60     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   HD                      63                 30
  CILON-T[@R34]              2011   716    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   SD                      64                 180
  Gao *et al*[@R35]          2013   428    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   SD                      56                 365
  Guan *et al*[@R36]         2012   840    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   SD                      60                 30
  HOST-ASSURE[@R37]          2013   1356   Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   Both                    63                 30
  Jeong *et al*[@R38]        2014   275    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   Both                    NR                 30
  Jin *et al*[@R39]          2012   60     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   HD                      62                 30
  Kim *et al*[@R40]          2011   126    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   HD                      62                 30
  Kim *et al*[@R41]          2007   60     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   SD                      63                 30
  Kum *et al*[@R42]          2009   66     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   SD                      62                 14
  Lee *et al*[@R43]          2010   63     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   Both                    NR                 14
  PIANO-2 CKD[@R44]          2011   74     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   Both                    53                 14
  Shim *et al*[@R45]         2009   379    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel   SD                      61                 14

ACCEL-AMI, adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in patients with AMI; ACCEL-LOADING-ACS, Multicentre Randomised Trial Evaluating Efficacy of Cilostazol on Platelet Aggregation, Inflammation and Myonecrosis in ACS Patients; ACCEL-POLYMORPHISM, Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention; ACCEL-PPI, Pharmacodynamics Effects of Adding Cilostazol versus Double-dose Clopidogrel in Patients with Acute Myocardial Infarction During Proton Pump Inhibitor Co-administration; ACCEL-RESISTANCE, Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance; CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; HD, high-dose clopidogrel (150 mg); HOST-ASSURE, Harmonising Optimal Strategy for Treatment of Coronary Artery Stenosis---Safety and Effectiveness of Drug-Eluting Stents and Antiplatelet Regimen; NR, not reported; PIANO-2 CKD, Platelet Reactivity in Patients with Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared with a High-Maintenance Dose of Clopidogrel; SD, Standard-dose clopidogrel (75 mg).

###### 

Inclusion criteria and study quality for platelet reactivity outcomes trials

  Trial                      Cohort                                                                             Definition of HTPR                                                    Platelet reactivity assay   Quality of study\*
  -------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------- --------------------
  ACCEL-AMI[@R29]            Patients with ACS undergoing PCI                                                   5 and 20 μM ADP-induced maximal platelet aggregation \>50%            VerifyNow P2Y12; LTA        +++
  ACCEL-LOADING-ACS[@R30]    Patients with non-ST-elevation MI undergoing PCI                                   NR                                                                    VerifyNow P2Y12             ±±±
  ACCEL-POLYMORPHISM[@R31]   Patients with high post-treatment platelet reactivity or diabetes undergoing PCI   5 μM ADP-induced maximal platelet aggregation \>50%                   VerifyNow P2Y12; LTA        +++
  ACCEL-PPI[@R32]            Patients with acute MI undergoing PCI                                              20 μM ADP-induced maximal platelet aggregation \>59%                  LTA                         ±±±
  ACCEL-RESISTANCE[@R33]     Patients with high on-treatment platelet reactivity undergoing PCI                 5 μM ADP-induced maximal platelet aggregation \>50%                   VerifyNow P2Y12; LTA        ++±
  CILON-T[@R34]              Patients with angina undergoing PCI                                                NR                                                                    VerifyNow P2Y12             ++±
  Gao *et al*[@R35]          Obese patients undergoing PCI                                                      Post-treatment platelet aggregation absolute difference 10% or less   LTA                         ±±±
  Guan *et al*[@R36]         Patients with ACS and high on-treatment platelet reactivity undergoing PCI         20 μM ADP-induced maximal platelet aggregation \>55%                  LTA                         ±±±
  HOST-ASSURE[@R37]          All-comer patients undergoing PCI                                                  NR                                                                    VerifyNow P2Y12             ±±+
  Jeong *et al*[@R38]        Patients with ACS undergoing PCI                                                   NR                                                                    LTA                         ±±±
  Jin *et al*[@R39]          Patients undergoing PCI                                                            \% platelet inhibition \<20                                           VerifyNow P2Y12; LTA        ±++
  Kim *et al*[@R40]          Patients with acute MI undergoing PCI                                              20 μM ADP-induced maximal platelet aggregation \>59%                  VerifyNow P2Y12; LTA        ++±
  Kim *et al*[@R41]          Patients with ST-elevation MI undergoing PCI                                       \% platelet inhibition \<20                                           VerifyNow P2Y12; LTA        ±±±
  Kum *et al*[@R42]          Patients undergoing PCI                                                            NR                                                                    VerifyNow P2Y12             ±±±
  Lee *et al*[@R43]          Patients with high on-treatment platelet reactivity undergoing PCI                 \% platelet inhibition \<20                                           VerifyNow P2Y12             +±±
  PIANO-2 CKD[@R44]          Patients with renal disease on haemodialysis undergoing PCI                        5 μM ADP-induced maximal platelet aggregation \>50%                   VerifyNow P2Y12; LTA        +++
  Shim *et al*[@R45]         Patients undergoing PCI with DES                                                   \% platelet inhibition \<20                                           VerifyNow P2Y12             +±±

\*Represents risk of bias based on: sequence generation of allocation; allocation concealment and blinding. '+' represents low bias risk, '−' high bias risk and '±' unclear bias risk.

ACCEL-AMI, adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in patients with AMI; ACCEL-LOADING-ACS, Multicentre Randomised Trial Evaluating Efficacy of Cilostazol on Platelet Aggregation, Inflammation and Myonecrosis in ACS Patients; ACCEL-POLYMORPHISM, Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention; ACCEL-PPI, Pharmacodynamics Effects of Adding Cilostazol versus Double-dose Clopidogrel in Patients with Acute Myocardial Infarction During Proton Pump Inhibitor Co-administration; ACCEL-RESISTANCE, Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance; ACS, acute coronary syndrome; CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; HD, high-dose clopidogrel (150 mg); HOST-ASSURE, Harmonising Optimal Strategy for Treatment of Coronary Artery Stenosis---Safety and Effectiveness of Drug-Eluting Stents and Antiplatelet Regimen; LTA, light transmittance aggregometry; MI, myocardial infarction; NR, not reported; PIANO-2 CKD, Platelet Reactivity in Patients with Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared with a High-Maintenance Dose of Clopidogrel; SD, Standard-dose clopidogrel (75 mg).

###### 

Baseline characteristics of included trials for cardiovascular outcomes

  Trial                           Year        N      Comparison                                                                            Follow-up (months)   Mean age (years)   DM (%)   Stent type           DES (%)
  ------------------------------- ----------- ------ ------------------------------------------------------------------------------------- -------------------- ------------------ -------- -------------------- ---------
  ABCD[@R46]                      2014        630    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 12                   65                 31       BES                  100
  ACCEL-AMI[@R29]                 2010        90     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 1                    62                 21       PES\>SES\>ZES        100
  ACCEL-LOADING-ACS[@R30]         2012        218    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 1                    63                 23       DES, BMS             95
  ACCEL-RESISTANCE[@R33]          2009        60     Aspirin/clopidogrel/cilostazol vs aspirin/high-dose clopidogrel                       1                    63                 23       DES                  100
  Ahn CM *et al*[@R47]            2011        130    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 24                   64                 22       SES                  100
  Chen YD *et al*[@R48]           2006        120    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 9                    58                 30       BMS                  0
  CIDES[@R49]                     2008        280    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 6                    62                 100      PES, SES             100
  CILON-T[@R34]                   2011        960    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 6                    64                 34       PES, ZES             100
  CLEAR[@R50]                     2011        120    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 6                    66                 42       SES\>ZES\>PES\>EES   100
  CREST[@R51]                     2005        705    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 6                    60                 26       BMS                  0
  DECLARE-DIABETES[@R52] [@R53]   2008/2010   450    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 24                   61                 100      PES, SES             100
  DECLARE-LONG[@R53] [@R54]       2007/2010   450    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 24                   61                 33       PES, SES             100
  DECLARE- LONG II[@R55]          2011        499    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 12                   62                 35       ZES                  100
  Gao *et al*[@R35]               2013        428    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 12                   56                 18       SES\>PES             100
  Guan *et al*[@R36]              2012        840    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 1                    60                 NR       DES                  100
  Han *et al*[@R56]               2009        1212   Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 12                   60                 22       BMS, DES             52
  Han *et al*[@R57]               2006        120    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 3                    61                 23       BMS, DES             43
  HOST-ASSURE[@R37]               2013        3755   Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 1                    63                 32       ZES-R\>EES-PtCr      100
  Hu *et al*[@R58]                2013        146    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 12                   63                 NR       NR                   NR
  Jin *et al*[@R39]               2012        60     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 1                    62                 45       DES                  100
  Kim *et al*[@R59]               2008        109    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 6                    68                 29       PES\>SES             100
  Kim *et al*[@R41]               2007        60     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 1                    63                 29       SES\>PES\>others     100
  Kum *et al*[@R42]               2009        603    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 6                    62                 26       DES                  100
  Lee *et al*[@R60]               2007        20     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 1                    56                 25       NR                   100
  LONG- DES-II[@R61] [@R62]       2007        500    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 9                    61                 33       PES, SES             100
  Lu *et al*[@R63]                2006        120    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 6--9                 71                 NR       BMS                  0
  Lu *et al*[@R64]                2007        402    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 6                    61                 44       BMS, DES             85
  Min *et al*[@R10]               2007        59     Aspirin/clopidogrel or ticlopidine/cilostazol vs aspirin/clopidogrel or ticlopidine   6                    62                 26       BMS                  0
  OPTIMUS-2[@R6]                  2008        50     Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 1                    64                 100      NR                   100
  Shen *et al*[@R65]              2010        160    Aspirin/Clopidogrel/Cilostazol vs Aspirin/Clopidogrel                                 12                   69                 100      DES                  100
  Suh *et al*[@R66]               2009        143    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 25                   62                 100      PES\>SES             100
  Wang *et al*[@R67]              2005        193    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 12                   62                 28       BMS                  0
  Wang *et al*[@R68]              2010        164    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 12                   68                 NR       BMS, DES             NR
  Zang *et al*[@R69]              2008        263    Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel                                 12                   59                 100      BMS, DES             53

ABCD, Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients with Long or Multivessel Coronary Artery Disease underwent Biolimus-Eluting Stent Implantation; ACS, acute coronary syndrome; AMI, acute myocardial infarction; BES, biolimus-eluting stent; BMS, bare metal stent; CIDES, comparison of cilostazol versus clopidogrel after drug-eluting stenting in diabetic patients; CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; CLEAR, The Cilostazol Administration Before Percutaneous Coronary Intervention for Reduction of Periprocedural Myonecrosis Trial; CREST, Coronary Stent Restenosis in Patients Treated with Cilostazol; DECLARE-LONG II: Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions; DECLARE-DIABETES, A Randomised Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients; DECLARE-LONG, Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions; DES, drug-eluting stent; DM, diabetes mellitus; EES, everolimus-eluting stent; EES-PtCr, everolimus-eluting platinum-chromium alloy stent; LONG-DES, Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease; OPTIMUS-2, Impact of Cilostazol on Platelet Function Profiles in Patients with Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy; PES, Paclitaxel-eluting stent; SES, Sirolimus-eluting stent; ZES, Zotarolimus-eluting stent; ZES-R, Zotarolimus-eluting Resolute stent.

Other trial expansions as in [tables 1](#OPENHRT2014000068TB1){ref-type="table"} and [2](#OPENHRT2014000068TB2){ref-type="table"}.

###### 

Inclusion criteria and study quality of included cardiovascular outcomes trials

  Trial                     Cohort                                                                       Quality of study\*
  ------------------------- ---------------------------------------------------------------------------- --------------------
  ABCD[@R46]                Patients with long or multivessel disease undergoing PCI                     ++±
  ACCEL-AMI[@R29]           Patients with ACS undergoing PCI                                             +++
  ACCEL-LOADING-ACS[@R30]   Patients with non-ST-elevation MI undergoing PCI                             ±±±
  ACCEL-RESISTANCE[@R33]    Patients with high on-treatment platelet reactivity undergoing PCI           ++±
  Ahn *et al*[@R47]         Patient with ACS undergoing PCI                                              ±±+
  Chen *et al*[@R48]        Patients with ACS undergoing PCI                                             ±++
  CIDES[@R49]               Patients with diabetes undergoing PCI                                        ±±±
  CILON-T[@R34]             Patients with angina undergoing PCI                                          ++±
  CLEAR[@R50]               Patients with stable angina undergoing PCI                                   ±±±
  CREST[@R51]               Patients with ACS/known stenosis undergoing PCI                              +++
  DECLARE-DIABETES[@R52]    Patients with ACS and diabetes undergoing PCI                                +±±
  DECLARE-LONG[@R54]        Patients with ACS and stenosis of long (\>25 mm) lesions undergoing PCI      +±±
  DECLARE-LONG II[@R55]     Patients with ACS/known stenosis of long (\>25 mm) lesions undergoing PCI    +++
  Gao *et al*[@R35]         Obese patients undergoing PCI                                                ±±±
  Guan *et al*[@R36]        Patients with ACS and high on-treatment platelet reactivity undergoing PCI   ±±±
  Han *et al*[@R56]         Patients with ACS undergoing PCI                                             ++±
  Han *et al*[@R57]         Patients with ACS undergoing PCI                                             ±±±
  HOST-ASSURE[@R37]         All-comer patients undergoing PCI                                            ±±+
  Hu *et al*[@R58]          Patients with ACS undergoing PCI                                             ±±±
  Jin *et al*[@R39]         Patients undergoing PCI                                                      ±++
  Kim *et al*[@R59]         Patients with ACS/known stenosis undergoing PCI                              ±±±
  Kim *et al*[@R41]         Patients with ST-elevation MI undergoing PCI                                 ±±±
  Kum *et al*[@R42]         Patients with ACS/known stenosis undergoing PCI                              ±±±
  Lee *et al*[@R60]         Patients undergoing elective PCI                                             +±±
  LONG-DES-II[@R61]         Patients with stenosis of long lesions undergoing PCI                        ++±
  Lu *et al*[@R70]          Patients undergoing PCI                                                      ±±+
  Lu *et al*[@R64]          Patients with ADP-induced platelet inhibition rates \<30% undergoing PCI     +±±
  Min *et al*[@R10]         Patients with ACS/known stenosis undergoing elective PCI                     ±+±
  OPTIMUS-2[@R6]            Patients with diabetes undergone PCI                                         +++
  Shen *et al*[@R65]        Patients with ACS undergoing PCI                                             ±±±
  Suh *et al*[@R66]         Patients with diabetes and chronic total occlusion undergoing PCI            ±±±
  Wang *et al*[@R67]        Patients with small vessel stenosis undergoing PCI                           ±±±
  Wang *et al*[@R68]        Patients with non-ST-elevation MI undergoing PCI                             ±±±
  Zang *et al*[@R69]        Patients with ACS undergoing PCI                                             ±±±

\*Represents risk of bias based on: sequence generation of allocation; allocation concealment and blinding. '+' represents low bias risk, '−' high bias risk and '±' unclear bias risk.

ABCD, Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients with Long or Multivessel Coronary Artery Disease underwent Biolimus-Eluting Stent Implantation; ACS, acute coronary syndrome; AMI, acute myocardial infarction; BES, biolimus-eluting stent; BMS, bare metal stent; CIDES, comparison of cilostazol versus clopidogrel after drug-eluting stenting in diabetic patients; CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; CLEAR, The Cilostazol Administration Before Percutaneous Coronary Intervention for Reduction of Periprocedural Myonecrosis Trial; CREST, Coronary Stent Restenosis in Patients Treated with Cilostazol; DECLARE-LONG II: Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions; DECLARE-DIABETES, A Randomised Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients; DECLARE-LONG, Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions; DES, drug-eluting stent; DM, diabetes mellitus; EES, everolimus-eluting stent; EES-PtCr, everolimus-eluting platinum-chromium alloy stent; LONG-DES, Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease; OPTIMUS-2, Impact of Cilostazol on Platelet Function Profiles in Patients with Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy; PES, Paclitaxel-eluting stent; SES, Sirolimus-eluting stent; ZES, Zotarolimus-eluting stent; ZES-R, Zotarolimus-eluting Resolute stent.

Other trial expansions as in [tables 1](#OPENHRT2014000068TB1){ref-type="table"} and [2](#OPENHRT2014000068TB2){ref-type="table"}.

Primary platelet reactivity outcomes {#s3c}
------------------------------------

### Primary outcome: differences in PRU {#s3c1}

TAPT resulted in a mean PRU reduction of 47.73 (95% CI −61.41 to −34.04, p\<0.0001; mean PRU 182.90 vs 232.65) compared with DAPT ([figure 2](#OPENHRT2014000068F2){ref-type="fig"}A). There was a larger mean difference between the TAPT and DAPT groups when the analysis was restricted to a DAPT group using standard-dose clopidogrel (mean PRU 189.54 vs 255.83) where the PRU value was lower by a mean of 64.10 (95% CI −84.35 to −43.85). Moreover, TAPT was associated with a lower PRU value even when compared with DAPT using high-dose clopidogrel (mean difference of 27.17) (mean PRU 176.27 vs 209.48) ([figure 2](#OPENHRT2014000068F2){ref-type="fig"}A). The results were similar when stratified by ACS status (see web appendix figure A1) or by baseline clopidogrel resistance status (see web appendix figure A2). There was moderate-to-high heterogeneity for the above analysis. However, the heterogeneity was reduced in subgroup analysis restricted to comparison with high-dose clopidogrel ([figure 2](#OPENHRT2014000068F2){ref-type="fig"}A), in trials enrolling patients with baseline clopidogrel resistance (see web appendix figure A2 and in trials enrolling patients without ACS (see web appendix figure A1).

![(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Secondary platelet reactivity outcome: difference in percent platelet inhibition after treatment between TAPT versus DAPT. (C) Secondary platelet reactivity outcome: risk of high on-treatment platelet reactivity (HTPR) after treatment between TAPT versus DAPT.](openhrt2014000068f02a){#OPENHRT2014000068F2}

![Continued](openhrt2014000068f02b){#OPENHRT2014000068F02B}

In addition, the mean PRU values on treatment in the TAPT group in each of the trials were below a PRU of 235, which has been cited in the literature as the suggested threshold for defining HTPR.[@R13]

### Secondary outcomes: percent platelet inhibition and high on-treatment platelet reactivity {#s3c2}

TAPT was associated with a 12.71% greater platelet inhibition compared to DAPT for the overall cohort (95% CI 10.76 to 14.67, p\<0.0001) ([figure 2](#OPENHRT2014000068F2){ref-type="fig"}B). TAPT was also associated with a greater platelet inhibition in comparison with DAPT using standard-dose clopidogrel (14.37% mean greater platelet inhibition) and remained significant even when compared with DAPT using high-dose clopidogrel (9.07% mean greater platelet inhibition) ([figure 2](#OPENHRT2014000068F2){ref-type="fig"}B). There was moderate heterogeneity for the above analysis. The results were similar when stratified by ACS status (see web appendix figure A3) or by baseline clopidogrel resistance status (see web appendix figure A4).

In addition, TAPT was associated with a 60% reduction in the risk of HTPR when compared with DAPT ([figure 2](#OPENHRT2014000068F2){ref-type="fig"}C) (relative risk=0.40; 95% CI 0.30 to 0.53, p\<0.0001). When stratified by clopidogrel dose, TAPT was associated with a 50% reduction in risk of HTPR compared to standard-dose DAPT and a 72% reduction compared to high-dose DAPT ([figure 2](#OPENHRT2014000068F2){ref-type="fig"}C). Heterogeneity was moderate with no evidence for significant publication bias. The results were similar when stratified by ACS status (see web appendix figure A5) or by baseline clopidogrel resistance status (see web appendix figure A6).

Cardiovascular outcomes {#s3d}
-----------------------

### Primary outcome {#s3d1}

TAPT was associated with a 32% reduction in the risk of MACE (IRR=0.68; 95% CI 0.60 to 0.78) when compared with DAPT for the overall cohort ([figure 3](#OPENHRT2014000068F3){ref-type="fig"}A). This effect was observed regardless of stent type (P~interaction~ \>0.05) such that even in patients undergoing PCI with DES, TAPT resulted in a 36% reduction in MACE (IRR=0.64; 95% CI 0.55 to 0.75) when compared with DAPT alone ([figure 3](#OPENHRT2014000068F3){ref-type="fig"}A). There was low heterogeneity in the analysis and no evidence for significant publication bias.

![(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Secondary cardiovascular outcome: risk of all-cause mortality between TAPT versus DAPT. (C) Secondary cardiovascular outcome: risk of myocardial infarction between TAPT versus DAPT. (D) Secondary cardiovascular outcome: risk of target lesion revascularisation (TLR) between TAPT versus DAPT. (E) Secondary cardiovascular outcome: risk of target vessel revascularisation (TVR) between TAPT versus DAPT. (F) Secondary cardiovascular outcome: risk of stent thrombosis between TAPT versus DAPT.](openhrt2014000068f03a){#OPENHRT2014000068F3}

![Continued](openhrt2014000068f03b){#OPENHRT2014000068F03B}

![Continued](openhrt2014000068f03c){#OPENHRT2014000068F03C}

### Secondary outcomes {#s3d2}

TAPT was associated with similar IRR for death (IRR=0.79; 95% CI 0.58 to 1.09) ([figure 3](#OPENHRT2014000068F3){ref-type="fig"}B), cardiovascular death (IRR=0.74; 95% CI 0.42 to 1.30) and MI (IRR=0.85; 95% CI 0.63 to 1.14) ([figure 3](#OPENHRT2014000068F3){ref-type="fig"}C) for the overall cohort. The IRR was independent of stent type as TAPT showed benefit regardless whether BMS and DES was used (stent type, P~interaction~ \>0.05). In the overall cohort, TAPT was associated with a 43% reduction in the risk of TLR (IRR=0.57; 95% CI 0.44 to 0.73) ([figure 3](#OPENHRT2014000068F3){ref-type="fig"}D) and a 31% reduction in the risk of TVR (IRR=0.69; 95% CI 0.59 to 0.81) ([figure 3](#OPENHRT2014000068F3){ref-type="fig"}E) compared with DAPT. TAPT efficacy for reducing TLR and TVR was present even when the analyses were restricted to studies using DES. In DES-treated patients, TAPT resulted in a 43% reduction in TLR (IRR=0.57; 95% CI 0.44 to 0.74) and a 35% reduction in TVR (IRR=0.65; 95% CI 0.54 to 0.79) with TAPT compared with DAPT.

TAPT was associated with significantly lower stent thrombosis rate when compared with DAPT (IRR=0.63; 95% CI 0.40 to 0.98) ([figure 3](#OPENHRT2014000068F3){ref-type="fig"}F). There was no heterogeneity (0%) in all of the above analyses and no evidence for significant publication bias.

### Safety outcomes {#s3d3}

TAPT was associated with a numerically increased risk of major (IRR=1.24; 95% CI 0.79 to 1.92) ([figure 4](#OPENHRT2014000068F4){ref-type="fig"}A), minor (IRR=1.37; 95% CI 0.88 to 2.14) ([figure 4](#OPENHRT2014000068F4){ref-type="fig"}B), or any bleeding (IRR=1.26; 95% CI 0.99 to 1.61) ([figure 4](#OPENHRT2014000068F4){ref-type="fig"}C) compared with DAPT, although these were not statistically significant. TAPT was also associated with a 59% increase in drug discontinuation due to adverse events (IRR=1.59; 95% CI 1.32 to 1.91) ([figure 4](#OPENHRT2014000068F4){ref-type="fig"}D) when compared with DAPT. The most commonly listed causes for drug discontinuation were headache, skin rash and palpitations/tachycardia. There was no-to-modest (for drug discontinuation outcomes) heterogeneity in all of the above analyses and no evidence for significant publication bias.

![(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Safety outcome: risk of minor bleeding between TAPT versus DAPT. (C) Safety outcome: risk of any bleeding between TAPT versus DAPT. (D) Safety outcome: risk of drug discontinuation due to adverse effects between TAPT versus DAPT.](openhrt2014000068f04a){#OPENHRT2014000068F4}
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Discussion {#s4}
==========

In patients undergoing PCI, TAPT using cilostazol results in significant decrease in platelet reactivity and reduced risk of HTPR. TAPT resulted in significantly lower mean PRU, greater platelet inhibition and reduced risk of HTPR in the setting of DAPT with both standard-dose and high-dose clopidogrel. In addition, TAPT was associated with a significant reduction in CV events, including reduction in MACE, driven largely by significant reductions in TLR and TVR. Most importantly, there was a significant lower stent thrombosis with TAPT versus DAPT. Moreover, the reduction of restenosis with TAPT remained even when the analysis was restricted to trials using DES. In addition, there was numerically higher bleeding with TAPT versus DAPT, although this did not reach statistical significant. However, there was a significant increase in the risk of drug discontinuation due to adverse effects when compared with DAPT.

Platelet reactivity and outcomes {#s4a}
--------------------------------

Prior studies have shown a relationship between on-treatment platelet reactivity and adverse CV events in patients undergoing PCI. In an analysis of individual patient data from six studies with 3059 patients, for every 10 U increase in PRU there was a 4% increase in primary endpoint rate of death, MI or stent thrombosis (HR 1.04; 95% CI 1.03 to 1.06; p\<0.0001).[@R17] A recent consensus statement recommended a cut-off of PRU \>235 U as the threshold for identifying patients with HTPR who may be at high risk for ischaemic or thrombotic events following PCI.[@R13] Patients with HTPR have been shown to have an increased risk of death (110% increase), MI (104% increase) and stent thrombosis (211% increase).[@R17] [@R18]

Although platelet reactivity is a surrogate marker, given the wide interindividual variability in clopidogrel-induced platelet inhibition,[@R1] various strategies have been tested to improve platelet inhibition. These strategies have utilised higher loading and maintenance doses of clopidogrel, or next-generation P2Y12 inhibitors such as prasugrel and ticagrelor, which are more potent that clopidogrel and have a more uniform antiplatelet effect. Doubling of the clopidogrel dose (150 mg) has been shown to significantly reduce PRU in patients with HTPR.[@R19] Similarly, data from the next-generation P2Y12 inhibitors such as prasugrel and ticagrelor have shown improved platelet reactivity indices when compared with clopidogrel.[@R22] Although the newer agents prasugrel and ticagrelor reduce MACE in randomised trials, these agents increase bleeding in patients with PCI and cost significantly more than generic clopidogrel.[@R23] [@R24]

Cilostazol, a phosphodiesterase III inhibitor, exhibits antiplatelet effects by increasing cAMP within platelets, and is available as a generic drug. Our results show a significant benefit of TAPT with cilostazol in improving platelet reactivity indices in patients undergoing PCI, with lower PRU, greater platelet inhibition and a significant reduction in the risk of HTPR regardless of comparison with either standard-dose or high-dose clopidogrel. In addition, these results were seen even in comparison with DAPT using high-dose clopidogrel. Given that generic clopidogrel is now available, many clinicians opt to prescribe high-dose clopidogrel to address HTPR in patients who cannot afford newer antiplatelet agents. The results of the present study show that TAPT with cilostazol is superior even to DAPT with high-dose clopidogrel. Despite these promising results, a number of limitations must be acknowledged. Although platelet reactivity is a risk factor/surrogate marker for adverse CV events, clinical studies have not yet demonstrated that a pharmacological treatment strategy based on platelet reactivity improves outcomes.[@R20] [@R25] In the ARCTIC trial of 2440 patients randomised to platelet-function monitoring and drug adjustment group versus conventional strategy of no monitoring and drug adjustment, there were no differences in composite of death, MI, stent thrombosis, stroke, or urgent revascularisation at 1 year between the two groups, calling into question the utility of adjusting therapies based on platelet function monitoring.[@R25]

However, because cilostazol inhibits both platelet activation and smooth muscle proliferation, it has the potential to target two dreaded complications of PCI---stent thrombosis and restenosis. TAPT may reduce MACE by two or more cellular mechanisms.[@R8] Our study shows significant reduction in both stent thrombosis and restenosis using TAPT with cilostazol, even in patients treated with DES. This is a potential advantage for this agent, as no antiplatelet agent, including prasugrel or ticagrelor, has been shown to have any antirestenosis property.

Therefore, a strategy of using TAPT with cilostazol has several advantages: (1) it improves the surrogate outcome of platelet reactivity relative to DAPT, including high-dose clopidogrel; (2) the antismooth muscle proliferative properties of cilostazol may make it an excellent agent to prevent restenosis resulting in reduced TVR even in patients treated with a DES; (3) the improvement in platelet reactivity indices translate into significant reduction in stent thrombosis and (4) the medication is available generically and is therefore less expensive than newer antiplatelet therapy. Thus, when used following PCI, TAPT with cilostazol has the potential to be a cost-effective therapy to improve clinical outcomes by reducing thrombotic events and restenosis. The results of this study therefore call for a randomised trial comparing a strategy of TAPT with DAPT using newer antiplatelet agents.

Our results differ from the studies of Jang *et al*[@R26] and Sakurai *et al*[@R27] in that these studies did not evaluate platelet reactivity outcomes and had far fewer trials than the current analysis. In our analysis, TAPT was associated with significant increase in drug discontinuation. The most commonly listed causes for drug discontinuation were headache, skin rash and palpitations/tachycardia. Sakurai *et al*[@R27] similarly found a significant increase in rash and gastrointestinal side effects with TAPT.

Study limitations {#s4b}
-----------------

As in other meta-analyses without individual patient data, we were unable to adjust for dosages of medication used or with compliance with assigned therapies. Given heterogeneity in the study protocols, clinically relevant differences could have been missed and are best assessed in a meta-analysis of individual patient data. Stroke would have been interesting to examine, as there is some evidence that cilostazol reduces stroke.[@R28] All of the trials did not report all of the outcomes. The subgroup analyses might suffer from multiple testing. In addition, the results need to be confirmed in an ethnically diverse population, as most of the trials were done in Asian populations. However, the CREST and the OPTIMUS-2 trials, performed mainly in a non-Asian population, showed similar efficacy of cilostazol when compared with controls. The individual trials did not provide sufficient data to stratify analyses by early versus newer generation DES.

Conclusions {#s4c}
-----------

In patients undergoing PCI, TAPT with cilostazol is associated with significantly improved platelet reactivity indices, even when compared with DAPT with high-dose clopidogrel, and is associated with significant reduction in CV events, including reduction in BMS and DES restenosis and stent thrombosis. The dual properties of antiplatelet and antiproliferative action, the availability as a generic medication combined with the above data makes TAPT with aspirin, clopidogrel and cilostazol an attractive and strong competitor for newer antiplatelet regimens and should be evaluated in future trials.
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